These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25380940)

  • 1. High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: single-center results.
    Charlinski G; Ziarkiewicz M; Boguradzki P; Wiater E; Torosian T; Dwilewicz-Trojaczek J; Wiktor-Jedrzejczak W
    Transplant Proc; 2014 Oct; 46(8):2877-81. PubMed ID: 25380940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
    D'Souza A; Dispenzieri A; Wirk B; Zhang MJ; Huang J; Gertz MA; Kyle RA; Kumar S; Comenzo RL; Peter Gale R; Lazarus HM; Savani BN; Cornell RF; Weiss BM; Vogl DT; Freytes CO; Scott EC; Landau HJ; Moreb JS; Costa LJ; Ramanathan M; Callander NS; Kamble RT; Olsson RF; Ganguly S; Nishihori T; Kindwall-Keller TL; Wood WA; Mark TM; Hari P
    J Clin Oncol; 2015 Nov; 33(32):3741-9. PubMed ID: 26371138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical investigation of primary amyloidosis with autologous hematopoietic stem cell transplantation].
    Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Wang WS; Li Y; Yin Y; Liang ZY; Cen XN; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):187-90. PubMed ID: 22781604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
    Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M
    Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.
    Sanchorawala V
    Acta Haematol; 2020; 143(4):381-387. PubMed ID: 32248194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V; Seldin DC
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
    Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
    N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
    Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
    Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
    Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
    Rosengren S; Mellqvist UH; Nahi H; Forsberg K; Lenhoff S; Strömberg O; Ahlberg L; Linder O; Carlson K
    Bone Marrow Transplant; 2016 Dec; 51(12):1569-1572. PubMed ID: 27694943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.